Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Chronic Sialorrhea Market Size Changed, over the years?
There has been robust growth in the market size of chronic sialorrhea in the past years. The market is projected to expand from a worth of $0.72 billion in 2024 to an estimated $0.76 billion in 2025, boasting a compound annual growth rate (CAGR) of 6.5%. The previous period’s growth can be accredited to factors such as the escalating incidence rate of neurological disorders, a rise in global population, enhanced awareness and diagnosis, and a growing preference for non-invasive medical treatment methods.
How Much Will the Chronic Sialorrhea Market Be Worth in 2029?
Significant expansion is anticipated in the chronic sialorrhea market over the coming years. The market is projected to reach $0.97 billion by 2029, growing at a CAGR of 6.2%. This growth is primarily due to an increasing awareness about available treatments, a growing need for more effective treatment methods, an increase in healthcare spending, an increase in pediatric cases, and an increasing demand for oral gels and liquids. Future trends to watch out for include the rise of telemedicine for remote patient monitoring, the implementation of patient-focused care models, innovations in pharmacology, the integration of speech and occupational therapies, and the creation of longer-lasting pharmaceuticals.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21149&type=smp
Which is the Largest Company in the Chronic Sialorrhea Market?
Major companies operating in the chronic sialorrhea market are Pfizer Inc., Eisai Co. Ltd., Ipsen Pharmaceuticals Inc., Aurobindo Pharma Limited, Shionogi Inc., Supernus Pharmaceuticals Inc., Granules India Limited, Hugel Inc., Medy-Tox Inc., Gufic Biosciences Limited, US WorldMeds LLC, Proveca Limited, Neos Therapeutics Inc., Merz Therapeutics GmbH, Taj Pharma India Limited, Meitheal Pharmaceuticals, Clini Experts Services Private Limited, NeuroHealing Pharmaceuticals Inc., ExCEEd Orphan Pharmaceuticals AG, Solstice Neurosciences Inc.
What Are the Main Market Drivers in the Chronic Sialorrhea Industry?
The burgeoning number of individuals plagued with neurodegenerative diseases is projected to stimulate the expansion of the chronic sialorrhea market in the future. Neurodegenerative diseases denote a class of conditions typified by the progressive destruction or demise of neurons in the brain and spinal cord. The escalation in these diseases stems from genetics and family histories, environment, a more profound comprehension of disease mechanisms, chronic health problems, and social and psychological influences. Chronic sialorrhea frequently accompanies neurodegenerative diseases like Parkinson’s and ALS, thereby necessitating treatments tailored to prevent aspiration, enhance overall oral functioning, and bolster patient comfort. For example, in September 2023, Parkinson’s UK, a charitable organization based in the UK, reported approximately 153,000 individuals in the UK presently grappling with Parkinson’s. As the population continues to age, this number is expected to see a rise of 20%, escalating to an estimated 172,000 individuals by 2030. Hence, the escalating occurrences of neurodegenerative diseases will act as a catalyst for the growth of the chronic sialorrhea market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21149&type=smp
How Is the Chronic Sialorrhea Market Segments Structured?
The chronic sialorrhea market covered in this report is segmented –
1) By Treatment Type: Pharmacological Treatments, Botulinum Toxin Injections, Surgical Interventions, Medical Devices And Assistive Therapies
2) By Route Of Administration: Oral Medications, Injectable Treatments, Topical Applications
3) By Patient Population: Pediatric Patients, Adult Patients
4) By End-User: Hospitals And Specialty Clinics, Rehabilitation Centers, Homecare Settings
Subsegments:
1) By Pharmacological Treatments: Anticholinergic Medications, Antidepressants, Alpha-adrenergic Agonists, Salivary Gland Modulators
2) By Botulinum Toxin Injections: Botulinum Toxin Type A (Botox), Botulinum Toxin Type B (Myobloc), Localized Salivary Gland Injections
3) By Surgical Interventions: Sialendoscopy, Salivary Gland Duct Dilation or Stenting, Parotid Duct Surgery, Submandibular Gland Removal (Sialadenectomy)
4) By Medical Devices And Assistive Therapies: Oral Dryness Devices, Salivary Stimulation Devices, Lip and Mouth Exercises, Artificial Salivary Glands
What Strategic Trends Are Transforming the Chronic Sialorrhea Market?
Primary businesses in the chronic sialorrhea market are striving to formulate innovative therapies such as oral solutions. These interventions aim to enhance patient adherence, offer less invasive alternatives, and promote more efficient and safer methods to manage chronic sialorrhea in children, while minimizing adverse effects. An oral solution refers to a liquid drug intended for oral consumption, incorporating an active ingredient suspended in a liquid medium, and made for effortless intake. For example, the UK-based Proveca Pharma Ltd. launched Sialanar (glycopyrronium bromide) in France in February 2023. This product aims to treat severe chronic sialorrhea in children suffering from neurological disorders. A unique feature of Sialanar is its liquid-based form intended for easy administration and precise dosages, which is particularly beneficial for children who find it challenging to take solid medications. Its efficacy and safety credentials are well documented, and it enables improved life quality by mitigating excessive drooling, a typical issue in neurodevelopmental disorders such as cerebral palsy.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/chronic-sialorrhea-global-market-report
Which Global Regions Offer the Highest Growth in the Chronic Sialorrhea Market?
North America was the largest region in the chronic sialorrhea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic sialorrhea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21149
This Report Delivers Insight On:
1. How big is the chronic sialorrhea market, and how is it changing globally?
2. Who are the major companies in the chronic sialorrhea market, and how are they performing?
3. What are the key opportunities and risks in the chronic sialorrhea market right now?
4. Which products or customer segments are growing the most in the chronic sialorrhea market?
5. What factors are helping or slowing down the growth of the chronic sialorrhea market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model